FLNA Company Profile and Key Details

Filana Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.98. This means the shares are trading below this model’s fair value.

Filana Therapeutics, Inc. (NASDAQ:FLNA) closed at $1.00 USD, losing -$0.01 (-1.20%) from the previous close of $1.01. The stock is currently within 5% of its 52-week low $0.98 and $4.98. With a market capitalization of about $48.21 million, Filana Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.74). Key stats such as the average daily volume over the past year has been around 383.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Austin, TX, Filana Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard Jon Barry, the company employs approximately 20 people and listed since July 14, 2000. Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies.

Filana Therapeutics, Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.72 suggesting the stock is closer to book value. The P/FCF stands at -1.76, also above market averages.

Valuation shows Filana Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 395.05% upside. Our AI forecast model points to short-term weakness (-5.94% over two weeks), a medium-term fall (-98.02% over three months), and a longer-term loss (-98.02% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Filana Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.94%, with price expected at $0.95 by August 04, 2026, within a range of $0.88 to $1.01 3-Month Outlook: Projected fall of -98.02%, reaching $0.02 by October 19, 2026, with a range of $0.01 to $0.03. 1-Year Outlook: Projected loss of -98.02%, with price at $0.02 by July 21, 2027, within a range of $0.01 to $0.03.